Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of SHR-3276 injection in patients with advanced solid tumors
CTR20243877Phase 2Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-3276 in Nonhematologic neoplasms, sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Dec 2024; status: active.
02
Drugs
SHR-3276
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20243877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243877.